These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 24532044)

  • 61. Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.
    Benson DM; Panzner K; Hamadani M; Hofmeister CC; Bakan CE; Smith MK; Elder P; Krugh D; O'Donnell L; Devine SM
    Leuk Lymphoma; 2010 Feb; 51(2):243-51. PubMed ID: 20038230
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP).
    Eom HS; Kim YK; Chung JS; Kim K; Kim HJ; Kim HY; Jin JY; Do YR; Oh SJ; Suh C; Seong CM; Kim CS; Lee DS; Lee JH
    Ann Hematol; 2010 May; 89(5):489-97. PubMed ID: 20012045
    [TBL] [Abstract][Full Text] [Related]  

  • 63. "IM iD"eally treating multiple myeloma.
    Lacy MQ
    Blood; 2013 Mar; 121(11):1926-8. PubMed ID: 23493767
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment of newly diagnosed multiple myeloma in transplant-eligible patients.
    Kumar S
    Curr Hematol Malig Rep; 2011 Jun; 6(2):104-12. PubMed ID: 21394431
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of Autologous Stem Cell Transplantation Combined with Modified VTD Regimen on Elderly Patients with Multiple Myeloma and Its Influence on miRNA Cytokines.
    Bai Z; Shen J
    Comput Math Methods Med; 2022; 2022():6320329. PubMed ID: 35222688
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma.
    Joks M; Jurczyszyn A; Machaczka M; Skotnicki AB; Komarnicki M
    Eur J Haematol; 2015 Feb; 94(2):109-14. PubMed ID: 25039659
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study.
    Horvath N; Spencer A; Kenealy M; Joshua D; Campbell PJ; Lee JJ; Hou J; Qiu L; Kalff A; Khong T; Londhe A; Siggins S; van Kooten Losio M; Eisbacher M; Prince HM
    Leuk Lymphoma; 2019 Sep; 60(9):2122-2133. PubMed ID: 30777794
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
    J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial.
    Tanaka K; Toyota S; Akiyama M; Wakimoto N; Nakamura Y; Najima Y; Doki N; Kakihana K; Igarashi A; Kobayashi T; Ohashi K; Kudo D; Shinagawa A; Takano H; Fujio T; Okoshi Y; Hori M; Kumagai T; Saito T; Mukae J; Yamamoto K; Tsutsumi I; Komeno T; Yoshida C; Yamamoto M; Kojima H;
    Acta Haematol; 2019; 141(2):111-118. PubMed ID: 30726834
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients.
    Wu S; Zheng C; Chen S; Cai X; Shi Y; Lin B; Chen Y
    Biomed Res Int; 2015; 2015():927105. PubMed ID: 26425561
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Advances in therapy of multiple myeloma.
    Bladé J; Rosiñol L
    Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Role of consolidation therapy in transplant eligible multiple myeloma patients.
    Cavo M; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Zamagni E
    Semin Oncol; 2013 Oct; 40(5):610-7. PubMed ID: 24135406
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma.
    Takamatsu H; Munemoto S; Murata R; Terasaki Y; Nakajima K; Nakao S
    Anticancer Res; 2013 Dec; 33(12):5681-5. PubMed ID: 24324117
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Bortezomib plus melphalan and prednisone for multiple myeloma.
    Islam A; Ambrus JL
    N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19073984
    [No Abstract]   [Full Text] [Related]  

  • 75. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival.
    Ferrero S; Ladetto M; Drandi D; Cavallo F; Genuardi E; Urbano M; Caltagirone S; Grasso M; Rossini F; Guglielmelli T; Cangialosi C; Liberati AM; Callea V; Carovita T; Crippa C; De Rosa L; Pisani F; Falcone AP; Pregno P; Oliva S; Terragna C; Musto P; Passera R; Boccadoro M; Palumbo A
    Leukemia; 2015 Mar; 29(3):689-95. PubMed ID: 25027515
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.
    Holmberg LA; Becker PS; Bensinger W
    Acta Haematol; 2017; 137(3):123-131. PubMed ID: 28355602
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Integrating novel therapies in the transplant paradigm.
    Harousseau JL
    Cancer J; 2009; 15(6):479-84. PubMed ID: 20010167
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy.
    Lee BH; Shin SH; Min CK; Yhim HY; Kwak JY; Kim JA
    Int J Hematol; 2013 May; 97(5):634-9. PubMed ID: 23605366
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Multiple myeloma--recent advances in diagnosis and treatment].
    Chou T
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):304-8. PubMed ID: 15791813
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.
    Kuroda J; Kobayashi T; Tsutsumi Y; Yamamoto M; Ohshiro M; Sasaki N; Shimura Y; Mizutani S; Nagoshi H; Kiyota M; Nakayama R; Uchiyama H; Matsumoto Y; Horiike S; Shimazaki C; Taniwaki M
    Int J Hematol; 2010 Nov; 92(4):669-72. PubMed ID: 20978877
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.